medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2011, Number 2

<< Back Next >>

Acta Med 2011; 9 (2)

Portal hypertension

Ibarrola-Calleja JL, Núñez BF, Rodríguez GM, Ordóñez-Céspedes J

Language: Spanish
References: 105
Page: 83-91
PDF size: 269.52 Kb.


ABSTRACT

Portal hypertension (HP) is a complex handling pathological condition. It is among the ten more frequent causes of mortality in Mexico and is defined as the increase of the portal system (SP) pressure over 12 mmHg. The most frequent etiology is hepatic cirrhosis (CH), so the HP sinusoidal intrahepatic type has the higher incidence. The pathophysiology of the HP is produced by an increment of splachnic vascular resistance and blood volume, conditions that result in systemic alterations and vascular and microvascular modifications, secondary to hormonal, endothelial and neuronal products, leading to all the clinical manifestations. All of these factors should be taken into a count to decide the management and therapeutics for each patient, aspects that are mentioned in this review.


REFERENCES

  1. Silva G. Hipertensión portal: definición, etiologías y evaluación. Gastroenterología Latinoamericana 2006; 17(2): 197–200.

  2. Álvarez BG. Hipertensión portal. Anales de Cirugía Cardiaca y Vascular 2002; 8(1): 46–55.

  3. Gutiérrez SC, Arruabarrena V, Campos SF. Fisiopatología del aparato digestivo. 3ª edición. Manual Moderno, 2006: 411–426.

  4. Morán VCA. Hipertensión portal. Texto de Cirugía. Editorial Poligráfica C.A. 1999: 568–601.

  5. Estadísticas de la Clínica de hipertensión portal. Instituto Nacional de la Nutrición Salvador Zubirán 1995.

  6. Pérez R. Baveno consensus workshop on portal hypertension. Gastr Latinoam 2007; 18(1): 65-68.

  7. Amico DG, García-Tsao G, Calés P, Escorsell A, Nevens F, Cestari R, Celetti G, Zoli M. Diagnosis of portal hypertension: How and when. In: de Francis R et al. Portal hypertension III proceedings of the third baveno international consensus workshop on definitions, methodology, and therapeutic strategies. Oxford: Blackwell Science; 2001: 36-65.

  8. Montaño-Loza A, Meza-Junco J. Patogénesis de la hipertensión portal. Rev Invest Clin V 2005: 57(4).

  9. Garrido A, Sánchez R, Espinoza V, Becerra M A, Padrón G. Signos de hipertensión portal por ultrasonido Doppler-color en pacientes cirróticos. Rev Hosp Jua Mex 2001; 68(1): 8-14.

  10. Krige JE, Beckingham IJ. ABC of disease of liver, pancreas and biliary system. Portal hypertension-1. BMJ 2001; 322: 348.

  11. Kapoor D, Sarin SK. Pathophysiology of portal hypertension. J Gastroenterol Hepatol 2002; 17: S482-S487.

  12. Suárez-Quintero J. Portal hypertension: your measurement in the practical clinical. Rev Col Gastroenterol 2007: 22(1).

  13. Graham DY, Smith JL. The courses of patients alter variceal hemorrhage. Gastroenterology 1981; 80: 800-9.

  14. Roberts LR, Kamath PS. Pathophysiology of variceal bleeding. Gastrointest Endose Clin North Am 1999; 9: 167-74.

  15. Huet PM, Pomier-Layrargues G, Villeneuve JP et al. Intrahepatic circulation in liver disease. Semin Liver Dis 1986; 6: 277-86.

  16. Boyer TD. Portal hypertensive hemorrhage: pathogenesis and risk factors. Semin Gastrointest Dis 1995; 6: 125-33.

  17. Franco A, Aristizábal G. Trauma del porta-hepatis. Colombia Médica 1994; 25: 58-60.

  18. Pera C. Hipertensión portal. Cirugía. Fundamentos, indicaciones y opciones técnicas. Masson, S.A. 1996: 579-886.

  19. Mudawi H, Ali Y, El Tahir M. Prevalence of gastric varices and portal hypertensive gastropathy in patients with Symmers periportal fibrosis. Annals of Saudi Medicine 2008; 28(1): 42-44.

  20. Gines P, Quintero E, Arroyo V et al. Compensated cirrhosis: Natural history and prognosis factors. Hepatology 1987; 7: 122-128.

  21. García-Tsao G. Current management of the complications of cirrhosis and portal hypertension: varices and variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-48.

  22. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A et al. Etiology of liver cirrosis in Mexico. Ann Hepatol 2004; 3: 30-33.

  23. Tomioka M, Calvo F, Siguas A, Sánchez L, Nava E, García U, Valdivia M, Reátegui E. Enfermedad veno-oclusiva asociada a la ingestión de humanrripa (Senecio tephrosioides). Revista de Gastroenterología del Perú 1995: 15(3).

  24. Vauthey JN, Tomczak RJ, Helmberger T et al. The arterioportal fistula syndrome: clinicopathologic features, diagnosis, and therapy. Gastroenterology 1997; 113: 1390-401.

  25. Estrada O, Mestres C, López-Boado M, Salmerón J, Visa J, García-Valdecasas JC. Posttraumatic intrapancreatic aortosplenic fistula causing portal hypertension. Asian Cardiovasc Thorac Ann 2003; 11: 272-274.

  26. Urtasun R, Nieto N. Células estrelladas hepáticas y estrés oxidativo. Revista Española de Enfermedades Digestivas Madrid 2007; 4: 99.

  27. González-Alonso R, Garrido E, Albillos A. Pre-primary prophylaxis of variceal bleeding. Rev Esp Enferm Dig V Madrid 2007; 12: 99.

  28. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med Epub 2008; 29(1-2): 119-29.

  29. García-Tsao G, Weist R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-372.

  30. Matsubara S, Ouchi K, Matsuno S. Portal venous pressure following splenectomy in patients with portal hypertension of differing etiology. Eur Surg Res 1992; 24: 372-7.

  31. Vauthey JN, Tomczak RJ, Helmberger T et al. The arterioportal fistula syndrome: clinicopathologic features, diagnosis, and therapy. Gastroenterology 1997; 113: 1390-401.

  32. Rector WG Jr., Robertson AD, Lewis FW et al. Arterial underfilling does not cause sodium retention in cirrhosis. Am J Med 1993; 95: 286-95.

  33. Kawada N, Tran-Thi TA, Klein H et al. The contraction of hepatic stellate cells stimulated with vasoactive substences. Possible involvement of endothelin-1 and nitric oxide in the regulation of sinusoidal tonus. Eur J Biochem 1993; 213: 815-23.

  34. Zhang JX, Pegoli W, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994; 266: G624-G632.

  35. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut Epub 2008; 57(9): 1300-14.

  36. Ready J, Rector WG Jr. Systemic hemodinamyc changes in portal hypertension. Semin Gastrointest Dis 1995; 6: 134-9.

  37. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.

  38. Ludwig J, Hashimoto E, Obata H et al. Idiophatic portal hypertension. Hepatology 1993; 17: 1157-62.

  39. Hillaire A, Bonte E, Denniger MH et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: A re-evaluation in 28 patients. Gut 2002; 51: 275-80.

  40. Farhad Z, Afsaneh A, Ramin S, Ali Z, Mehdi M. Celiac disease as a potential cause of idiopathic portal hypertension: a case report. Journal of Medical Case Reports 2009, 3: 68doi:10.1186/1752-1947-3-68.

  41. Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol 2002; 17: S204-S213.

  42. Moschos J, Leontiadis G, Kelly C, Henry J, Kadis S. Idiopathic portal hypertension complicating systemic sclerosis: a case report. BMC Gastroenterology 2005; 1(5): 16.

  43. Tefferi A, Mesa RA, Nagorney DM et al. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.

  44. Arroyo V. Fisiopatología de la ascitis refractaria y el síndrome hepatorrenal. Nefrología 2002; XXII(5).

  45. Gines P, Arroyo V. Hepatorrenal síndrome. J Am Soc Nephrol 1999; 10: 1833-1839.

  46. Arroyo V, Ginés P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal síndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176.

  47. Nishida O, Moriyasu F, Nakamura T et al. Interrelationship between splenic and superior mesenteric venous circulation manifested by transient splenic arterial occlusion using a balloon catéter. Hepatology 1987; 7: 442-446.

  48. Strassburg CP. Gastrointestinal disorders of the critically ill. Shock liver. Best Pract Res Clin Gastroenterol 2003; 17: 369-81.

  49. Zeitoun J, Chryssostalis A, Terris B, Prat F, Gaudric M, Chaussade S. Portal hypertensive duodenal polyp: A case report. World J Hastroenterol 2007; 13(9): 1451-1452.

  50. Sandblom P. The history of portal hypertension. J R Soc Med 1993; 86: 544-6.

  51. Kozareck RA, Botoman VA, Bredfeldt JE, Roach JM, Patterson DJ, Ball TJ. Portal colopathy: prospective study of colonoscopy in patients with portal hypertension. Gastroenterology 1991; 101: 1192-1197.

  52. Bini EJ, Lascarides CE, Micale PL, Weinshel EH. Mucosal abnormalities of the colon in patients with portal hypertension: an endoscopic study. Gastrointest Endosc 2000; 52: 511-516.

  53. Heneghan MA, Byrne A, Harrison PM. An open pilot study of the effects of a human fibrin glue for endoscopic treatment of patients with acute bleeding from gastric varices. Gastrointest Endosc 2002; 56(3): 422-426.

  54. Yang WL, Tripathi D, Therapondos G, Todd A, Hayes PC. Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol 2002; 97(6): 1381-1385.

  55. McCormack TT, Sims J, Eyre-Brook I, Kennedy H, Goepel J, Johnson AG, Triger DR. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985; 26: 1226-1232.

  56. Gupta R, Saraswat VA, Kumar M, Naik SR, Pandey R. Frequency and factors influencing portal hypertensive gastropathy and duodenopathy in cirrhotic portal hypertension. J Gastroenterol Hepatol 1996; 11: 728-733.

  57. Misra SP, Dwivedi M, Misra V, Gupta M. Ileal varices and portal hypertensive ileopathy in patients with cirrosis and portal hypertension. Gastrointest Endosc 2004; 60: 778-783.

  58. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122: 521-9.

  59. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-68.

  60. Dobritz M, Nomayr A, Bautz W, Fellner FA. Gamna-Gandy bodies of the spleen detected with MR imaging: A case report. Magn Reson Imaging 2001; 19: 1249-51.

  61. Schrier RW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrosis. Hepatology 1988; 8: 1151-1157.

  62. Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32: 157-170.

  63. Ros J, Claria J, Jiménez W et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrosis. Hepatology 1995; 22: 915-920.

  64. Mukherjee S, Roy H K, Zetterman RK. Hepatorenal Syndrome. Emedicine Medscape’s Continually Updated Clinical Reference, Updated: 2009.

  65. Idrovo V. Encefalopatía hepática. Revista Colombiana de Gastroenterología. Rev Col Gastroenterol Bogotá 2003: 18(3).

  66. Blei A, Córdoba BRF. Pathogenesis of the encephalopathy new insights from neuroimagining and molecular studies. J Hepatol 2003; 39: 278-285.

  67. Ong JP, Aggarwal A, Krieger D et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-193.

  68. Ortiz M, Córdoba J, Dovals E et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther 2007; 26: 859-867.

  69. Atterbury CE, Maddrey WC, Conn HO, Neomycin-sorbitol and lactulose in treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406.

  70. Romero-Gómez M, Boza F, Garca-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-23.

  71. Amodio P. Health related quality of life and minimal hepatic encephalopathy. It is time to insert “quality” in health care. J Gastroenterol Hepatol 2009; 24: 329-30.

  72. Bosch J, García-Pagan JC, Berzigotti A, Abraldes J. Measurement of portal pressure and its role in the management of chronic liver disease. Sem Liv Dis 2006; 26: 348-362.

  73. Groszmann RJ, Glickman M, Beli A et al. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979; 76: 253-258.

  74. Vizzutti F, Arena U, Rega L, Pinzani M. Non invasive diagnosis of portal hipertension in cirrhotic patients. Gastroenterol Clin Biol 2008; 32(6 Suppl 1): 80-7.

  75. Martínez S, Carrión J. La elastografía (Fibroscan) en las enfermedades hepáticas. JANO 2008: 1-715.

  76. Dib N, Konate A, Oberti F, Calès P. Non-invasive diagnosis of portal hypertension in cirrhosis. Application to the primary prevention of varices. Gastroenterol Clin Biol 2005; 29(10): 975-87.

  77. Fernández P, Jiménez S, García M, Rebollo B, Herrerias G. Efecto hemodinámico esplácnico de somatostatina y octreótido en cirróticos. Estudio con ultrasonografía Doppler. Rev Esp Enferm Dig 2008; 100(9): 552-9.

  78. Ladero QJM, Gallego B. Derivación transyugular intrahepática portosistémica. Revis Gastroenterol 2000; 2: 147-158.

  79. Abraldes JG, Angermayr B, Bosch J. The management of portal hypertension (review). Clin Liver Dis 2005; 9: 685-713, vii.

  80. Matloff D. Treatment of acute variceal bleeding. Gastroenterol Clin North Am 1992; 21: 103.

  81. Walker S. Vasoconstrictor therapy and bleeding esophageal varices. Hepatogastroenterology 1990; 37: 538-543.

  82. Escorsell A, Bordas JM, del Arbol LR, Jaramillo JL, Planas R, Banares R et al. Randomized controlled trial of sclerotherapy versus somatostatin infusión in the prevention of early rebleeding following acute varicela hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. J Hepatol 1998; 29(5): 779-788.

  83. Shields R, Jenkins SA, Baxter JN et al. A prospective randomized controlled trial comparing the efficacy of somatostatin and injection sclerotherapy in the control of bleeding of esophageal varices. J Hepatol 1992.

  84. Castañeda BR. Tratamiento farmacológico de la hipertensión portal. Rev Gastroenterol 2005: 70(3).

  85. Vinel JP, Lamouliatte H, Cales P, Combis J, Roux D, Desmorat H, Pradere B, Carjonnet G, Quinton A, Pascal J. Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before vericeal obliteration. Gastroenterology 1992; 102: 1760.

  86. Silvain C, Carpentier S, Sautereau S et al. A randomized trial of glypressin plus transdermal nitroglycerin versus ictreotide in the control of acute variceal hemorrhage. Hepatology 1991 1939: 15.

  87. Puoti C, Bellis L. Steatosis and portal hypertension. European Review for medical and Pharmacological Sciencies 2005; 9: 285-290.

  88. Banares R, Albillos A, Rincón D, Alonso S, Gonzalez M, Ruiz-del-Arbol L et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute varicela bleeding: a meta-analysis. Hepatology 2002; 35(3): 609-615.

  89. Rosado B, Kamath PS. Trasjugular intrahepatic portosystemic shunts: An update. Liver Transpl 2003; 9: 207-217.

  90. Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol 2007; 41 (Suppl 3): S344-51.

  91. Terblanche J, Burrow A, Hobbs HF. Controversies in the Management of the bleeding of esophageal varices. New England J Med 1989: 320-1993.

  92. Rosemurgy AS, Goode SE, Zwiebel BR, Black TJ, Brady PG. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portocaval shunts in the treatment of bleeding varices. Ann Surg 1996; 224(3): 378-384.

  93. Rosemurgy AS, Serafini FM, Zweibel BR, Black TJ, Kudryk BT, Nord HJ et al. Transjugular intrahepatic portosystemic shunt versus small-diameter prosthetic H-graft portocaval shunt: extended follow-up of an expanded randomized prospective trial. J Gastrointest Surg 2000; 4(6): 589-597.

  94. Luca A, Amico GD, La Galia R. TIPS for prevention of recurrant rebleeding in patients with cirrosis: meta-analysis of randomized clinical trials. Radiology 1999; 212: 411-421.

  95. Stanley AJ, Jalan R, Forrest EH. Long term follow up of transjugular intrahepatic portosistemic shunt for the treatment of portal hypertension: results in 130 patients. Gut 1996; 39: 479-485.

  96. Helton WS, Maves R, Wicks K, Johansen K. Transjugular intrahepatic portasystemic shunt versus surgical shunt in good-risk cirrhotic patients: a case-control comparison. Arch Surg 2001; 136(1): 17-20.

  97. Sauer P, Hansmann J, Richter GM, Stremmel W, Stiehl A. Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy 2002; 34(9): 690-697.

  98. Echenagusía A, Camuñez F, Simó G. Shunt portocava transyugular percutáneo. En: Diagnóstico y terapéutica endoluminal. José Martín Carreira Ed. Masson 2002; 19(4): 462-476.

  99. Mercado M, Takahashi T, Rojas G. Cirugía en hipertensión portal, ¿en qué paciente y cuál operación? Revista de Investigación Clínica 1993; 45(4): 329-337.

  100. Escorsell A, Banares R, García-Pagan JC, Gilabert R, Moitinho E, Piqueras B et al. TIPS versus drug therapy in preventing varicela rebleeding in advenced cirrosis: a randomized controlled trial. Hepatology 2002; 35(2): 385-392.

  101. Russo MW, Zacks SL, Sandler RS, Brown RS. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 2000; 31(2): 358-363.

  102. Tefferi A, Barrett SM, Silverstein MN et al. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol 1994; 46: 325-328.

  103. Cello JP, Grendell JH, Crass RA, Trunkey DD, Cobb EE, Heilbron DC. Endoscopic sclerotherapy versus portocaval shunt in patients with severe cirrhosis and varicela hemorrhage. N Eng J Med 1984; 311(25): 1589-1594.

  104. Mercado MA, Orozco H, Vasquez M, Pantoja J P, Contreras A, Catzin Kuhlmann A, Flores A, Rodríguez-Dávalos M. Comparative study of two variants of a modified esophageal transection in the Sugiura-Futagawa operation. Arch Surg 1998; 133: 1046-1049.

  105. Yasuo I, Norihiro K, Kensho S, Yasutsugu B. Sugiura Procedure for Management of variceal bleeding in Japan. World Journal Surgery 1994; 18: 216-221.




2020     |     www.medigraphic.com